Home| About us| My LA: login/register| For authors| For reviewers| Submit a paper
(close)

(Ctrl-click to select multiple journals)


How should we address you?

Your email address


 Yes, sign up now
 Sign up for general news too

Privacy Statement
 
 
 

Translational Oncogenomics

Synopsis: An open access, peer reviewed electronic journal that covers novel genetic, epigenetic and molecular pathway information related to clinical cancer.


Indexing: 6 major databases. Pubmed indexing for NIH-funded research.

Processing time: Decision in 2 weeks for 90% of papers.

Visibility: Most popular article read 2000+ times.

RSS

NEWS

TWITTER
View factor
for journal
52288


About this journal

ISSN: 1177-2727


Aims and scope:

The primary mission of Translational Oncogenomics is to provide an open-access, peer-reviewed, rapid-publication forum to assist in the dissemination of novel genetic, epigenetic and molecular pathway information related to clinical cancer.

The journal is designed to meet the scientific and public need for such a forum in order to process the accelerating acquisition of genomic data resultant from recent technological advances in and international programmatic commitments to this area of research. Particularly encouraged is the submission of papers with a translational connection to human cancer from basic science to ethical considerations related to the application of oncogenomic discoveries for diagnostic and prognostic purposes in clinical trials and for anti-cancer drug development.

An important objective will be to contribute information published in this forum to comprehensive internationally-accessible genomic databases in order to foster the identification of molecular targets for the therapy of specific cancers.

The following topics of interest are structured on the premise that cancer is a highly heterogeneous disease involving elements in the host as well as in the tumor itself:

  • Constitutional cancer susceptibility factors
  • Polymorphic variants and linkage disequilibrium related to cancer risk
  • Somatic genetic and epigenetic events related to cancer initiation
  • Precancerous genetic and epigenetic alterations
  • Somatic genetic and epigenetic events related to cancer progression
  • Genetic and epigenetic events related to metastases
  • Genetic and epigenetic events related to tumor/normal cell/tissue interactions
  • Mutation identification in cancer
  • Gene copy number abnormalities in cancer
  • Gene rearrangements in cancer
  • Oncogene and suppressor gene discovery and characterization
  • MicroRNAs in cancer
  • Molecular pathway alterations related to genetic or epigenetic alterations
  • Genomic methylation effects on gene transcription profiles
  • Gene expression profiles related to cancer classification and progression
  • Gene transcript splicing variations related to cancer
  • Constitutional variations affecting anti-cancer drug efficacy and toxicity
  • Genetic or epigenetic alterations related to drug sensitivity or resistance
  • Gene expression profiles related to drug sensitivity or resistance
  • Genomic stratification and monitoring applications in clinical trials
  • Integration of genomic and clinical database information
  • Technological advances in genomics
  • Quality control and ethical issues related to applied oncogenomics

Editorial standards and procedures:

Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers.  Reviewers are required to provide fair, balanced and constructive reports.  

Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair.  Appeals are considered by the Editor in Chief or Associate Editor.

Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.

Indexing:

This journal is indexed by the following services:

  • Embase
  • Embiology
  • Google Scholar
  • CAS
  • DOAJ

SPARC Europe Seal award winner:

This journal has been awarded a SPARC Europe Seal. The Seal is an initiative of SPARC Europe (Scholarly Publishing and Academic Resources Coalition) and the Directory of Open Access Journals (DOAJ) which is awarded to journals applying a Creative Commons CC-BY copyright license and that make journal metadata accessible to DOAJ.  

Amongst other important services DOAJ makes metadata OAI-compliant.  This in turn enhances the visibility of papers and allows OAI-harvesters to include the details of journal articles in their services. We encourage readers to make use of this valuable resource.  The DOAJ search page is available here.

National Institutes of Health Public Access Policy compliant:

As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.

If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf. 



 
 
 


The Oncogene Mcts1

Authors: Ali Hachem and Suvobroto Nandi
Publication Date: 19 Jul 2007
Translational Oncogenomics 2007:2 79-84

Ali Hachem1 and Suvobroto Nandi2

1The Cancer Center of Huntsville, Huntsville, AL 35801. 2Department of Medicine, University of California San Diego. 9500 Gilman Drive, M/C 0838, La Jolla, CA 92093.

Abstract: The oncogene MCTS1, discovered as an amplified product in a subset of T-cell lymphoma lines, has been implicated in cell cycle progression and conferring a growth advantage in lymphomas and breast cancer. Recent research shows that it modulates the MAPK pathway and acts as a translational activator both in vivo and in vitro. In breast cancer cells, expression of MCTS1 confers aggressive properties and inhibits apoptosis. This article will review these data and its implications on our understanding of cancer.

Categories: Oncology , Oncogenomics


Post comment




No comments yet...Be the first to comment.

Bookmark this article

LINKEDIN FACEBOOK

Add to Mixx! MIXX YAHOO! BUZZ

PERMALINK DIGG


Sign up for free journal updates

How should we address you?
Your email address
 Yes, sign up now


Recently published in this journal

Gene Expression Patterns in Myelodyplasia Underline the Role of Apoptosis and Differentiation in Disease Initiation and Progression
- 29/May/2008

Protein Multifunctionality: Principles and Mechanisms
- 15/May/2008

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
- 23/Apr/2008

Implication of Ceramide, Ceramide 1-Phosphate and Sphingosine 1-Phosphate in Tumorigenesis
- 10/Apr/2008

GRIM-19: A Double-edged Sword that Regulates Anti-Tumor and Innate Immune Responses
- 17/Mar/2008

Obesity, Adipocytokines and Cancer
- 17/Mar/2008

Oncogenic Role of Engrailed-2 (En-2) in Prostate Cancer Cell Growth and Survival
- 03/Mar/2008

Possible Imprinting and Microchimerism in Chronic Lymphocytic Leukemia and Related Lymphoproliferative Disorders
- 10/Feb/2008

Roles of Prohibitin in Growth Control and Tumor Suppression in Human Cancers
- 10/Feb/2008

Six Genes Associated with the Clinical Phenotypes of Individuals with Deficient and Proficient DNA Repair
- 10/Feb/2008

bHLH-Orange Transcription Factors in Development and Cancer
- 10/Dec/2007

A STAT3 Gene Expression Signature in Gliomas is Associated with a Poor Prognosis
- 11/Nov/2007

The Role of Src Family Kinases in Prostate Cancer
- 14/Oct/2007

Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)
- 23/Jul/2007

The Oncogene Mcts1
- 19/Jul/2007

YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression
- 11/May/2007

Tumor Suppressor Role of Notch1 and Raf-1 Signaling in Medullary Thyroid Cancer Cells
- 03/May/2007

Tetracycline Regulated Systems in Functional Oncogenomics
- 28/Mar/2007

Epigenetic Markers for Bladder Cancer in Urine
- 22/Mar/2007

Current Concepts on the Pathogenesis of the Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia
- 28/Feb/2007

Kidney Toxicogenomics of Chronic Potassium Bromate Exposure in F344 Male Rats
- 27/Feb/2007

Mithramycin Targets Sp1 and The Androgen Receptor Transcription Level: Potential Therapeutic Role in Advanced Prostate Cancer
- 26/Feb/2007

c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer
- 25/Feb/2007

Messenger RNA Detection in Leukemia Cell lines by Novel Metal-Tagged in situ Hybridization using Inductively Coupled Plasma Mass Spectrometry
- 24/Feb/2007

In Silico Promoter Analysis can Predict Genes of Functional Relevance in Cell Proliferation: Validation in a Colon Cancer Model
- 14/Feb/2007



Related journals...